US OptionsDetailed Quotes

TRVI241220P3000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Trevi Therapeutics Stock Discussion

Trytosaveabit

Nov 8 18:29

News 13D/A

$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-New Enterprise Associates 16, L.P.(18.7%),NEA Partners 16, L.P.(18.7%), etc.
SEC· 28 mins ago

Stock_Drift

Oct 4 15:15

After Hours Ticks. 4:14pm EST.

$A2Z Cust2Mate Solutions (AZ.US)$ $Upexi (UPXI.US)$ $Psyence Biomedical (PBM.US)$ $Prairie Operating (PROP.US)$ $Trevi Therapeutics (TRVI.US)$ $Pop Culture (CPOP.US)$ $China Pharma (CPHI.US)$ $Planet Green (PLAG.US)$ $Genius Group (GNS.US)$ $Arcadium Lithium (ALTM.US)$ $TuanChe (TC.US)$ $Nxu Inc (NXU.US)$

Trytosaveabit

Dec 5, 2023 06:32

Update

$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) 2 MINUTES AGO, 7:30 AM EST VIA PR NEWSWIRE

Trytosaveabit

Oct 13, 2023 07:37

Update

$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis 5 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE TRVI SHARE Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & V...